home / stock / bivi / bivi news


BIVI News and Press, BioVie Inc. From 05/10/24

Stock Information

Company Name: BioVie Inc.
Stock Symbol: BIVI
Market: OTC
Website: biovieinc.com

Menu

BIVI BIVI Quote BIVI Short BIVI News BIVI Articles BIVI Message Board
Get BIVI Alerts

News, Short Squeeze, Breakout and More Instantly...

BIVI - Expected US Company Earnings on Friday, May 10th, 2024

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...

BIVI - BioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment

2024-04-29 08:23:10 ET More on BioVie Inc. BioVie stock plunges 43% following public offering pricing BioVie slumps 18%, prices $21M equity offering Seeking Alpha’s Quant Rating on BioVie Inc. Historical earnings data for BioVie Inc. Financial ...

BIVI - BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the blood brain barrier, could represent a novel oral treatment targeting a...

BIVI - BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

“Bezisterim” has been approved as the non-proprietary name for NE3107 Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioV...

BIVI - BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, to...

BIVI - Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern ...

BIVI - DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 17, 2024) - Faruqi & Faruqi, LLP, a leading national se...

BIVI - BIVI 4-DAY DEADLINE ALERT: Hagens Berman Encourages BioVie (BIVI) Investors with Substantial Losses to Contact Firm Before Mar. 19th Deadline

SAN FRANCISCO, March 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now . Class Period: Aug. 5, 2021 – Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: ww...

BIVI - SHAREHOLDER REMINDER: Berger Montague Reminds BioVie Inc. (BIVI) Investors of the March 19, 2024 Deadline

Philadelphia, Pennsylvania--(Newsfile Corp. - March 13, 2024) - A securities fraud lawsuit has been filed against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI). The lawsuit is captioned Olmstead v. BioVie Inc. et al. , No. 3:24-cv-00035 (D. Nev.), and is filed on behalf of purchasers of...

BIVI - DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 11, 2024) - Faruqi & Faruqi, LLP, a leading national se...

Previous 10 Next 10